Aysenur Elmali

Dr. Aysenur Elmali


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2019 in Cureus
Verified
Journal Article
Open access
PDF file
MYMelek Tugce Yilmaz
Melek Tugce Yilmaz
AEAysenur Elmali
Aysenur Elmali
GYGozde Yazici
Gozde Yazici
The abscopal effect is mediated by a systemic anti-tumor immune response and reflects the regression of non-irradiated metastatic lesions at a distance from the primary site of irradiation. This review will focus on understanding the biological rationale behind the abscopal effect of radiotherapy (RT), which has a recently renewed interest as a result of the successes achieved with immunotherapy and RT in combination. Both RT and immunotherapy are standard components of modern treatment regimens. Combination of these two modalities results in an increased response in the irradiated lesions themselves and the metastatic regions distant from the site of irradiation. We will summarize the abscopal effect of radiotherapy, in particular, the synergistic effect of RT and immunotherapy.

29 October 2018 in Cureus
Verified
Journal Article
Open access
PDF file
GYGozde Yazici
Gozde Yazici
IGIbrahim Gullu
Ibrahim Gullu
MCMustafa Cengiz
Mustafa Cengiz
AEAysenur Elmali
Aysenur Elmali
MYMelek T. Yilmaz
Melek T. Yilmaz
GOGokhan Ozyigit
Gokhan Ozyigit
Treatment options for recurrent/metastatic sinonasal cancer (RMSNC) patients are limited. We present two cases with RMSNC treated with a combination of immune checkpoint blockade and hypo-fractionated stereotactic radiotherapy (HSRT). Case 1 presented with RMSNC three months after the primary treatment. The patient progressed under first-line chemotherapy and pembrolizumab was offered. The disease progressed after the sixth cycle. We performed reirradiation with HSRT to the primary site. Case 2 presented with local recurrence eight years after the primary treatment for maxillary sinus cancer. He refused surgery and chemotherapy and was offered nivolumab treatment. After two doses, we performed reirradiation with HSRT. Case 1 showed regression at both the local and the metastatic sites after radiotherapy. The second patient’s symptoms resolved completely three months after radiotherapy. The HSRT and immune checkpoint blockade combination is a promising treatment option for patients with RMSNC.

1 November 2021 in Experimental Eye Research
Verified
Journal Article
Closed access
AEAysenur Elmali
Aysenur Elmali
IKIrem Koc
Irem Koc
SCSamiye Yabanoglu Ciftci
Samiye Yabanoglu Ciftci
Emirhan NemutluEmirhan Nemutlu
Emirhan Nemutlu
SSSelcuk Surucu
Selcuk Surucu
GYGozde Yazici
Gozde Yazici

5 August 2024 in Strahlentherapie und Onkologie
Verified
Journal Article
Open access
PDF file
AEAysenur Elmali
Aysenur Elmali
OGOzan Cem Guler
Ozan Cem Guler
BDBirhan Demirhan
Birhan Demirhan
MYMelek Yavuz
Melek Yavuz
COCem Onal
Cem Onal
Purpose: This study sought to determine the predictive and prognostic value of clinicopathological parameters and neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and hemoglobin (Hgb) level in predicting recurrence patterns and locoregional relapse-free survival (LRFS) and distant metastasis-free survival (DMFS) in cervical cancer patients receiving definitive chemoradiotherapy (ChRT). Methods: This study included 261 cervical cancer patients treated with ChRT. The primary endpoints were the predictors of local recurrence (LR) and distant metastasis (DM), whereas the secondary endpoints were LRFS and DMFS. The association of survival with potential prognostic factors was analyzed using Cox regression analysis, and the predictors of LR and DM were identified using logistic regression analysis. Results: The median follow-up time was 10.9 years. Recurrences occurred in 132 patients (50.6%) within a median of 11.2 months after definitive ChRT. NLR and PLR values were significantly higher in patients with LR and DM than in those without, with no significant differences in Hgb levels in patients with or without LR and DM. In the multivariable logistic regression analysis, lymph node metastasis, elevated NLR, and low Hgb level were significantly correlated with LR and DM. In the multivariable analysis, large tumor size, presence of lymph node metastasis, and elevated NLR were the independent predictors for poor LRFS and DMFS, and Hgb level was an additional prognostic factor for DMFS. Conclusion: Hematological markers, particularly NLR and Hgb, may serve as cost-effective and readily accessible indicators for predicting recurrence and survival in cervical cancer patients, contributing to their practical use in routine assessments.

6 September 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
ASApurva Singh
Apurva Singh
WMWilliam Silva Mendes
William Silva Mendes
SOSang-Bo Oh
Sang-Bo Oh
OGOzan Cem Guler
Ozan Cem Guler
AEAysenur Elmali
Aysenur Elmali
LRLei Ren
Lei Ren
To predict metastasis-free survival (MFS) for patients with prostate adenocarcinoma (PCa) treated with androgen deprivation therapy (ADT) and external radiotherapy using clinical factors and radiomics extracted from primary tumor and node volumes in pre-treatment PSMA PET/CT scans. Our cohort includes 134 PCa patients (nodal involvement in 28 patients). Gross tumor volumes of primary tumor (GTVp) and nodes (GTVn) on CT and PET scans were segmented. A 5 mm expansion ring area outside primary tumor was defined. Z-score normalization was applied to radiomics features extracted from tumor and ring; dimension reduction was performed using Principal Components Analysis (PCA). For patients with only primary tumor, we took 3 principal components (PCs) from GTVp and one ring PC as representative radiomics components from CT and PET scans. For patients with nodes, we calculated weighted average (by volume) of radiomics from primary tumor and nodes, computed first 3 PCs and combined it with 1st PC from the ring. Radiomics PCs and clinical variables (age, Gleason score, initial prostate specific antigen value (i PSA), PSA_relapse) formed the predictors. Due to MFS data imbalance (metastasis-24, no metastasis-110), we performed 70:30 train-test split and applied imbalance correction to training data. Univariate Cox-regression was used to select top predictors (logistic regression p < 0.05). Multivariate Cox-regression was performed on imbalance-corrected training data and fit on testing data (using predictors selected from training). Model 2 was built using clinical variables and radiomic PCs from primary tumors (GTVp, ring). Model 3 was built using clinical variables only. Binary classification analysis for prediction of five-year MFS was also performed. Results of time-to-event analysis (MFS) were: Cox-regression c-scores: model1: train- 0.77 [0.72, 0.78]; test- 0.69 [0.64, 0.70]; model2: train- 0.72 [0.66, 0.73]; test- 0.63 [0.58, 0.64]; model3: train- 0.62 [0.57, 0.63]; test- 0.54 [0.51, 0.56]. The results of 5 year MFS classification analysis were [sensitivity, specificity, AUC]: model 1: train- [83.6 %, 91.3 %, 0.88]; test- [76.3 %, 82.5 %, 0.81]; model 2: train- [77.4 %, 85.1 %, 0.84]; test- [71.5 %, 78.2 %, 0.76]; model 3: train- [69.3 %, 78.2 %, 0.76]; test- [64.7 %, 72.6 %, 0.68]. The two cohorts of patients classified by model 1 showed statistically significant differences in their actual survival curves, demonstrating the efficacy of the classification. Integration of node with primary tumor-radiomics provides the best prognostic performance in MFS prediction. This is one of the first studies to explore the prognostic value of pre-treatment PSMA-PET, a relatively recent advancement in the care of prostate adenocarcinoma patients. Results demonstrated the potential of using imaging biomarkers from PSMA-PET/CT images for prognosis prediction before the treatment, which provides clinicians valuable information for customizing the treatment paradigm to improve the outcomes for primary prostate cancer patients.

6 August 2024 in The Prostate
Verified
Journal Article
Open access
COCem Onal
Cem Onal
OGOzan C. Guler
Ozan C. Guler
NTNese Torun
Nese Torun
AEAysenur Elmali
Aysenur Elmali
PSPhilip Sutera
Philip Sutera
PTPhuoc T. Tran
Phuoc T. Tran
Purpose: To assess the early metabolic response of the primary tumor using Gallium‐68 (68Ga)‐labeled‐prostate‐specific membrane antigen positron emission tomography (68Ga‐PSMA‐PET/CT), as well as the relationship between PSMA change in the primary tumor and PSA response after definitive radiotherapy (RT), either alone or in combination with androgen deprivation therapy (ADT) in intermediate risk prostate cancer (IR‐PCa) patients.Methods: The clinical data of 71 IR‐PCa patients treated with RT alone (36 patients, 50.7%) or RT and ADT (35 patients, 49.3%) were retrospectively analyzed. The difference between pre‐ and Posttreatment primary tumor PSMA expression and serum PSA values measured 4 months after completion of treatment were compared between treatment arms. Correlation between primary tumor metabolic response and serum PSA changes was analyzed.Results: The median duration between pre‐ and Posttreatment 68Ga‐PSMA‐PET/CT for the entire patient population was 6.9 months (range, 5.6–8.4 months), and it was similar in both treatment arms. A decrease in primary tumor maximum standardized uptake value (SUVmax) was seen in 66 patients (93.0%), with a median value of 61.2%, which is significantly lower in patients undergoing RT alone than those undergoing RT and ADT (45.1 ± 30.6% vs. 59.1 ± 24.7%; p = 0.004). The complete metabolic response rate was significantly higher in patients undergoing RT and ADT than those treated with RT alone (40% vs. 0%; p < 0.001). Although moderate and positive correlation between pretreatment SUVmax and oosttreatment SUVmax was observed, there was no significant correlation between SUV change and PSA change. For patients treated with RT and ADT, posttreatment SUVmax was significantly lower and SUV change was significantly higher in patients with PSA nadir than in those without.Conclusions: Our preliminary results show that RT, with or without ADT, significantly reduces primary tumor SUVmax and serum PSA levels. Nonetheless, our findings indicate that early treatment response using 68Ga‐PSMA‐PET/CT is not feasible for those treated with RT alone, and it may only be useful in better distinguishing patients with and without PSA nadir for those who received both RT and ADT.